News and Trends 20 Feb 2018 This Gene Therapy for Vision Loss is Safe and Effective After Two Years The results of a long-term follow-up suggest that GenSight’s gene therapy for Leber hereditary optic neuropathy can provide safe and effective treatment for the genetic cause of vision loss. GenSight develops gene therapies to preserve or restore vision in patients with neurodegenerative diseases of the retina. The biotech’s lead candidate is GS010, which is currently […] February 20, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Best in Biotech 20 Feb 2018 Money, Money, Money! Europe’s Best-Funded Biotechs in 2018 Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where many of us re-examine our finances and budget for the year ahead. With money on the brain, we thought it would be a good time to do a roundup of Europe’s best-funded private biotechs. With over €400M raised to date, […] February 20, 2018 - 11 minutesmins - By Karen O’Hanlon Cohrt Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 The FDA Backs a Bacterial Enzyme to Treat a Rare Autoimmune Disease The FDA has awarded Hansa Medical’s lead candidate for the treatment of an autoimmune disease with Orphan Drug Designation, which will support its journey through clinical development. Swedish biotech, Hansa Medical, develops enzymes that can help to control the immune system for transplantations and the treatment of autoimmune diseases. The company’s lead candidate, IdeS, has […] February 19, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Is Novartis’ Psoriasis Drug Going to Steal Humira’s Crown? Two clinical studies have demonstrated the capacity of Novartis’ monoclonal antibody to treat both plaque and scalp psoriasis and improve patient quality of life. Not only is Novartis leading the CAR-T cell therapy field with the approval of Kymriah last year, the big pharma is also developing drugs for diseases affecting the immune system. The company presented […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 Organ-on-a-Chip Technology Used to Spot New Hepatitis B Drug Targets Scientists in London are the first in the world to test how pathogens like the hepatitis B virus interact with artificial human organs. Researchers at Imperial College London have used artificial human organs, or organs-on-chips, to replicate the make-up and physiology of the cells in whole organs. The study, published in Nature Communications, shows how the […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 19 Feb 2018 Taking CAR-T Cells Beyond Cancer: A New Therapy for Autoimmune Disease CAR-T cells are all the rage as the latest treatment for cancer. But what if we could apply this same technology to treat autoimmune disease? Curious to learn whether this new technology could revolutionize yet another field of medicine, I talked to Stephane Boissel, CEO of TxCell, to discuss the future of the field and his […] February 19, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2018 French Biotech Gets a CRISPR Patent for CAR-T Research Update (16/02/2018): On top of the European patent it got last July, Cellectis now also has two US patents to use CRISPR technology to make CAR-T cells. Cellectis has said it will offer licenses to companies that want to use CRISPR gene editing in T cells. Not just for inserting CAR antigens, but also other editions […] February 16, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2018 This Mobile Diabetes Management System Can Reduce Hypoglycemia by 39% The wireless system for diabetes management developed by Cellnovo can significantly reduce life-threatening events of hypoglycemia in patients with type 1 diabetes. A clinical study that followed type 1 diabetes patients for a year has concluded that a new mobile system for diabetes management could reduce events of hypoglycemia by 29% in adults — from […] February 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 15 Feb 2018 Startup Studio Raises €90M to Create and Develop Exciting Young Biotechs iBionext has closed its Growth Fund, which has raised money from investors like Bpifrance to help young biotechs to reach their potential. iBionext is a French ‘startup studio’ that specializes in the creation and development of startups in the healthcare industry. It has closed its iBionext Growth Fund at €90M, which will be used to finance […] February 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 14 Feb 2018 This Biotech Veteran Is Using These Tips for Successful Drug Development, Here Is Why Our second interview at Refresh in Vienna was with Peter Llewellyn-Davies, the founder of Accellerate Partners and Apeiron’s CFO and CBO. He told us how he found himself at the biotech and shared the lessons he learned on his way there. Peter Llewellyn-Davies founded Accellerate Partners in 2012, which offers services including corporate expansion, funding […] February 14, 2018 - 5 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Anti-Antibiotic Resistance Technology Gets Fast-Tracked to Phase III Allecra Therapeutics’ candidate that blocks the development of antibiotic resistance has been awarded the FDA’s Fast Track Designation and will enter Phase III this summer. Allecra Therapeutics, our biotech of the week a few weeks ago, develops new treatments for multidrug-resistant Gram-negative bacterial infections. The company has received Fast Track Designation from the FDA and will begin […] February 14, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email